Martin G.
- Country
- Slovakia
- Department
- Psychiatricke oddelenie
Research Overview
- Long-term Safety Evaluation of Iclepertin in Schizophrenia Patients Post-Completion of Phase III Trials
- Evaluation of Valbenazine as Adjunctive Therapy in Schizophrenia Patients with Inadequate Antipsychotic Response: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
- Long-term Safety and Efficacy of Aticaprant as Adjunctive Therapy in Adults and Elderly with Major Depressive Disorder: An Open-label Study
Data & Insights
Has run more than one trial at 70 of 204 partner sites.
Specializations
Psychiatric Disorders
This investigator specializes in the treatment of severe psychiatric conditions, with particular emphasis on schizophrenia and major depressive disorder (MDD).
- Treatment-Resistant Conditions
- Adjunctive Therapy Approaches
- Long-term Safety Evaluation
The research focus includes innovative therapeutic approaches for patients with inadequate response to conventional treatments.
Therapeutic Innovation
The investigator explores novel therapeutic compounds including aticaprant, iclepertin, and valbenazine for psychiatric conditions.
- Antidepressant Augmentation
- Cognitive Impairment Treatment
- Antipsychotic Enhancement
Research activities center on developing adjunctive treatments to improve standard therapeutic regimens.
Clinical Outcomes
The investigator evaluates comprehensive treatment outcomes in psychiatric disorders, focusing on both efficacy and safety parameters.
- Symptom Management
- Safety Monitoring
- Treatment Tolerability
Special attention is given to long-term safety and therapeutic effectiveness in chronic psychiatric conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.